Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
Abivax (ABVX) has announced its Annual General Meeting scheduled for June 6, 2025, in Paris, France. The company provided updates on its key operational milestones, particularly highlighting the progress of its Phase 3 ABTECT clinical program. Enrollment completion for the ABTECT induction trials is expected in Q2 2025, with top-line induction results anticipated in Q3 2025.
In a show of confidence in the company's future, CEO Marc de Garidel revealed that the executive leadership team, including himself, invested in approximately 120,000 Abivax ordinary shares in Q1 2025. The company, which focuses on developing therapeutics for chronic inflammatory diseases, views 2025 as a potentially transformative year with major clinical readouts approaching.
Abivax (ABVX) ha annunciato la sua Assemblea Generale Annuale, prevista per il 6 giugno 2025 a Parigi, Francia. L'azienda ha fornito aggiornamenti sui principali traguardi operativi, evidenziando in particolare i progressi del programma clinico di Fase 3 ABTECT. Il completamento delle iscrizioni per gli studi di induzione ABTECT è previsto per il secondo trimestre 2025, con i risultati principali dell'induzione attesi nel terzo trimestre 2025.
In segno di fiducia nel futuro dell'azienda, l'amministratore delegato Marc de Garidel ha rivelato che il team esecutivo, incluso lui stesso, ha investito in circa 120.000 azioni ordinarie Abivax nel primo trimestre 2025. L'azienda, che si concentra sullo sviluppo di terapie per malattie infiammatorie croniche, considera il 2025 un anno potenzialmente trasformativo, con importanti risultati clinici imminenti.
Abivax (ABVX) ha anunciado su Junta General Anual programada para el 6 de junio de 2025 en París, Francia. La compañía proporcionó actualizaciones sobre sus hitos operativos clave, destacando especialmente el avance de su programa clínico de Fase 3 ABTECT. Se espera que la finalización de la inscripción para los ensayos de inducción ABTECT sea en el segundo trimestre de 2025, con los resultados principales de la inducción anticipados para el tercer trimestre de 2025.
En una muestra de confianza en el futuro de la empresa, el CEO Marc de Garidel reveló que el equipo ejecutivo, incluido él mismo, invirtió aproximadamente en 120,000 acciones ordinarias de Abivax en el primer trimestre de 2025. La compañía, que se enfoca en desarrollar terapias para enfermedades inflamatorias crónicas, considera que 2025 podría ser un año transformador con importantes resultados clínicos próximos.
Abivax (ABVX)는 2025년 6월 6일 프랑스 파리에서 연례 주주총회를 개최할 예정이라고 발표했습니다. 회사는 주요 운영 이정표에 대한 업데이트를 제공하며, 특히 3상 ABTECT 임상 프로그램의 진행 상황을 강조했습니다. ABTECT 유도 시험의 등록 완료는 2025년 2분기로 예상되며, 주요 유도 결과는 2025년 3분기에 발표될 예정입니다.
회사의 미래에 대한 신뢰를 보여주기 위해 CEO 마크 드 가리델은 자신을 포함한 경영진이 2025년 1분기에 약 120,000주의 Abivax 보통주에 투자했다고 밝혔습니다. 만성 염증성 질환 치료제 개발에 주력하는 이 회사는 2025년을 주요 임상 결과가 다가오는 잠재적으로 변혁적인 해로 보고 있습니다.
Abivax (ABVX) a annoncé la tenue de son Assemblée Générale Annuelle prévue le 6 juin 2025 à Paris, France. La société a fourni des mises à jour sur ses principales étapes opérationnelles, mettant particulièrement en avant les progrès de son programme clinique de Phase 3 ABTECT. La fin du recrutement pour les essais d'induction ABTECT est attendue au deuxième trimestre 2025, avec les résultats principaux d'induction prévus au troisième trimestre 2025.
Pour témoigner de sa confiance en l'avenir de l'entreprise, le PDG Marc de Garidel a révélé que l'équipe de direction, y compris lui-même, a investi environ 120 000 actions ordinaires Abivax au premier trimestre 2025. L'entreprise, qui se concentre sur le développement de traitements pour les maladies inflammatoires chroniques, considère 2025 comme une année potentiellement transformative avec des résultats cliniques majeurs à venir.
Abivax (ABVX) hat seine Jahreshauptversammlung für den 6. Juni 2025 in Paris, Frankreich, angekündigt. Das Unternehmen gab Updates zu seinen wichtigsten operativen Meilensteinen und hob insbesondere den Fortschritt des Phase-3-ABTECT-Studienprogramms hervor. Der Abschluss der Einschreibungen für die ABTECT-Induktionsstudien wird für das zweite Quartal 2025 erwartet, mit den wichtigsten Induktionsdaten im dritten Quartal 2025.
Als Zeichen des Vertrauens in die Zukunft des Unternehmens gab CEO Marc de Garidel bekannt, dass das Führungsteam, einschließlich ihm selbst, im ersten Quartal 2025 rund 120.000 Abivax-Stammaktien erworben hat. Das Unternehmen, das sich auf die Entwicklung von Therapeutika für chronisch-entzündliche Erkrankungen spezialisiert hat, sieht 2025 als potenziell wegweisendes Jahr mit bevorstehenden wichtigen klinischen Ergebnissen.
- Executive leadership team demonstrated confidence by purchasing 120,000 shares in Q1 2025
- Phase 3 ABTECT clinical program progressing on schedule
- None.
Insights
Abivax confirms Phase 3 clinical trial timeline remains on track with key results expected in Q3 2025, maintaining development momentum.
Abivax has reaffirmed its Phase 3 ABTECT program remains on schedule, with enrollment completion expected in Q2 2025 and top-line induction results anticipated in Q3 2025. For clinical-stage biotechnology companies, maintaining development timelines is critical, as delays often signal operational challenges or emerging safety concerns.
The ABTECT trials represent a pivotal inflection point for Abivax's development of therapeutics targeting chronic inflammatory diseases. These studies evaluate the company's approach to stabilizing immune response through natural regulatory mechanisms—a differentiated strategy in the inflammatory disease space.
The anticipated Q3 2025 data readout will provide crucial validation for Abivax's technology platform. With a
The timing of this announcement—coinciding with AGM details—suggests management's confidence in executing their clinical development strategy according to plan, which is essential for maintaining both investor trust and operational momentum in advance of these key milestones.
Executive team purchased 120,000 shares in Q1, signaling confidence ahead of critical clinical data expected in Q3 2025.
The disclosure of insider purchasing activity represents a tangible vote of confidence from Abivax's leadership. The executive team, including CEO Marc de Garidel, collectively acquired approximately 120,000 ordinary shares during Q1 2025. At the current
Insider buying at this scale is particularly noteworthy for a clinical-stage biotech with a
The strategic framing of these purchases as demonstrating "confidence in the Company's long-term value creation" and creating "alignment with shareholders" indicates the executive team's commitment to the company's developmental pathway. This financial commitment becomes especially meaningful as Abivax approaches what the CEO describes as a potentially "transformative year" with "major clinical readouts."
While executive share purchases never guarantee clinical or commercial success, this level of financial commitment from those with the closest view of operations frequently correlates with positive organizational momentum and management's favorable assessment of risk-reward dynamics.
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
- Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, France
- Phase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025
PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General Meeting will be held on June 6, 2025, in Paris, France.
Additional information and preparatory documents for this Annual General Meeting will be made available in the coming weeks in accordance with applicable legal and regulatory requirements.
This announcement comes as Abivax continues to execute against critical 2025 operational milestones, including the ongoing Phase 3 ABTECT clinical program. The Company confirmed that it remains on track to complete induction trials enrollment in the second quarter of 2025, with top-line induction data expected in the third quarter of 2025.
Marc de Garidel, Chief Executive Officer of Abivax, commented: "With major clinical readouts approaching, we believe 2025 has the potential to be a transformative year for Abivax. To demonstrate our confidence in the Company’s long-term value creation, the executive leadership team, including myself, made the decision to invest in approximately 120,000 Abivax ordinary shares in Q1 2025. This reinforces our alignment with shareholders as we advance toward potential commercialization."
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow Abivax on LinkedIn and on X, formerly Twitter, @Abivax.
Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
+1 847 987 4878
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business objectives. Words such as “anticipate,” “continue,” “expect,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying the therapeutic potential of Abivax's drug candidates, Abivax’s expectations regarding the availability of data and timing of reporting results from its clinical trials, including its Phase 3 ABTECT-1 and ABTECT-2 induction trials and Phase 3 ABTECT maintenance trial, and other statements that are not historical fact. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for, securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
FAQ
When will Abivax (ABVX) release its Phase 3 ABTECT trial results?
How many shares did Abivax executives purchase in Q1 2025?
What is the focus of Abivax's Phase 3 ABTECT clinical program?
When is Abivax's 2025 Annual General Meeting?
